Nektar Therapeutics
Stock Forecast, Prediction & Price Target
Nektar Therapeutics Financial Estimates
Nektar Therapeutics Revenue Estimates
Nektar Therapeutics EBITDA Estimates
Nektar Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $101.90M N/A | $92.05M -9.66% | $90.12M -2.09% | Avg: $66.41M Low: $24.13M High: $87.51M avg. -26.30% | Avg: $67.46M Low: $29.51M High: $82.03M avg. 1.57% | Avg: $127.70M Low: $55.86M High: $155.28M avg. 89.28% | Avg: $208.77M Low: $91.33M High: $253.87M avg. 63.48% |
Net Income
% change YoY
| $-523.83M N/A | $-368.19M 29.71% | $-276.05M 25.02% | Avg: $-174.74M Low: $-191.90M High: $-68.40M avg. 36.70% | Avg: $-184.06M Low: $-205.20M High: $-43.70M avg. -5.33% | Avg: $-138.73M Low: $-177.69M High: $-37.27M avg. 24.62% | Avg: $-101.65M Low: $-130.19M High: $-27.31M avg. 26.72% |
EBITDA
% change YoY
| $-453.79M N/A | $-220.53M 51.40% | $-243.10M -10.23% | Avg: $-66.41M Low: $-87.51M High: $-24.13M avg. 72.67% | Avg: $-67.46M Low: $-82.03M High: $-29.51M avg. -1.57% | Avg: $-127.70M Low: $-155.28M High: $-55.86M avg. -89.28% | Avg: $-208.77M Low: $-253.87M High: $-91.33M avg. -63.48% |
EPS
% change YoY
| -$2.86 N/A | -$1.97 31.11% | -$1.45 26.39% | Avg: -$0.69 Low: -$1.01 High: -$0.36 avg. 52.11% | Avg: -$0.63 Low: -$1.08 High: -$0.23 avg. 9.97% | Avg: -$0.73 Low: -$0.94 High: -$0.2 avg. -16.81% | Avg: -$0.54 Low: -$0.69 High: -$0.14 avg. 26.72% |
Operating Expenses
% change YoY
| $523.11M N/A | $310.65M -40.61% | $190.90M -38.54% | Avg: $61.60M Low: $22.38M High: $81.17M avg. -67.72% | Avg: $62.57M Low: $27.37M High: $76.09M avg. 1.57% | Avg: $118.44M Low: $51.81M High: $144.03M avg. 89.28% | Avg: $193.64M Low: $84.71M High: $235.48M avg. 63.48% |
FAQ
What is Nektar Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 20.68% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -191.90M, average is -174.74M and high is -68.40M.
What is Nektar Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 32.01% in 2025-2028.
We have gathered data from 5 analysts. Their low revenue estimate is $24.13M, average is $66.41M and high is $87.51M.
What is Nektar Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 18.00% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.01, average is -$0.69 and high is $-0.36.
What is the best performing analyst?
In the last twelve months analysts have been covering Nektar Therapeutics stock. The most successful analyst is Mara Goldstein.